Intersect ENT touts economic data from from Propel study

Intersect ENT (NSDQ:XENT) said today that budget impact data on its Propel steroid releasing implant for treating chronic sinusitis showed upfront costs offset by savings post-operatively. The data was presented at the International Society for Pharmaeconomics and Outcomes Research annual meeting in Milan, Italy. “A previous study demonstrated the use of Propel in sinus surgery for medically refractory chronic sinusitis may be a cost-effective intervention for preventing medical and surgical intervention following sinus surgery. This complementary analysis demonstrates the ‘affordability’ for a payor or self-funded employer which will continue to assist in the making appropriate coverage decisions,” study author Dr. Luke Rudmik of the University of Calgary said in a press release. The study reported that using propel had a “negligible impact” of -3¢ to 2¢ per member per month for self-insured employers or U.S. commercial payors. Upfront cost was offset by savings associated with reduced post-operative inflammation and scarring probabilities and their treatment costs, the Menlo Park, Calif.-based company said. Intersect ENT said refractory chronic sinusitis results in productivity costs to employers of over $10,000 per patient annually due to lost work days. “Chronic sinusitis is one of the top 10 most costly conditions to U.S. employers – associated with a heavy societal productivity cost of more than $12 billion annually in the U.S. In...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Drug-Device Combinations Otolaryngology Ear, Nose & Throat Surgical Intersect ENT Inc. Source Type: news